The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cell cycle progression score to modify treatment decisions in prostate cancer: Results of an ongoing registry trial.
E. David Crawford
Consultant or Advisory Role - Myriad Genetics
Honoraria - Myriad Genetics
Ashok J. Kar
No relevant relationships to disclose
Mark C. Scholz
Research Funding - Myriad Genetics
Jeffrey E. Fegan
No relevant relationships to disclose
Rajesh R. Kaldate
Employment or Leadership Position - Myriad Genetics
Stock Ownership - Myriad Genetics
Michael K. Brawer
Employment or Leadership Position - Myriad Genetics
Stock Ownership - Myriad Genetics